Contraindication

Targeted air flow was effective without drugs

Updated evidence-based strategies aim to improve colonoscopy bowel preparation quality and patient experience and propose a 90% benchmark for adequate bowel preparation.

While most Americans are protected, some groups could benefit from another shot

In PRESTIGE-AF, robust ischemic protection offset by recurrent ICHs

FDA says yes to novel combination of meloxicam and rizatriptan

Increased menstrual blood loss can be hard to measure and may detract from a woman's quality of life, but a range of treatment options are available.

No disparity emerges, though, in discussing weight-loss surgery with a healthcare provider

Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis

MIT engineers designed a type of gastric balloon that can be inflated and deflated as needed, offering an alternative for people who don't want to undergo more invasive treatments such as gastric bypass surgery, or people who don't respond well to weight-loss drugs.

An international committee of experts reached consensus on which patients with hair loss could benefit from LDOM, how to prescribe it, and how to monitor patients on treatment.

Can electronic systems help put more of our annual visit recommendations into action?

Medscape Medical News

When it was prescribed within a week of SARS CoV-2 infection, metformin was associated with a 53% reduction in long COVID or death.

Alcohol-related increase in PVCs suggests more attention to ventricular arrhythmias

Arimoclomol (Miplyffa) greenlit for ultra-rare genetic disorder

More than 5 million Americans in treatment for depression could benefit from therapy with psilocybin -- the active ingredient in "magic mushrooms," a new study finds.

Clinicians should perform liver blood tests before and during Veozah treatment

Changes in colchicine pharmacokinetics due to drug-drug interactions did not result in meaningful changes in its safety and effectiveness, according to a secondary analysis of a clinical trial.

Medicare's expanded coverage for semaglutide meant that around one in seven Medicare beneficiaries with a high BMI would be newly eligible for semaglutide treatment.

Until 2017, no FDA approved options existed for serious side effect of dopamine-blocking drugs